Pharmaceuticals maker Lupin has appointed a new head of quality for the company, as it strives to remain compliant with international safety and manufacturing norms throughout its vast manufacturing base across the world.
Johnny Mikell, the new global head of quality, comes from a similar role at Canada-based pharmaceutical manufacturer Apotex, and has 35 years of experience in the pharmaceutical industry, Lupin said.
“We have a strong Quality and Compliance team and having Johnny at the helm will help us achieve our near-term goal of ensuring that our sites are compliant and long-term goal of being the best when it comes to Quality and Compliance,” said Lupin MD Nilesh Gupta.
Lupin, as an India-based supplier of drugs to highly regulated markets such as the US and Europe, has to ensure global levels of compliance with safety and cleanliness norms, or risk losing access to these markets.
Lupin is the eighth largest generics pharmaceutical company in the world and is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID spaces.
It is also the leader in the Anti-TB segment.
Johnny Mikell, who will work out of Lupin’s US offices, has worked as Global Head of Quality and Compliance at Amneal.
He also worked at UCB, Novartis and Bausch & Lomb.
Mikell holds a Bachelor of Science degree in Biology and Master of Science in Microbiology and is an alumnus of Duke University, London’s British Standards Institute and Harvard.